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Abstract
IMPORTANCE Chronic hepatitis C virus (HCV) infection is a global health problem. The World Health
Assembly recently pledged to eliminate HCV by 2030. However, in Pakistan, a country with one of
the highest prevalence rates, the feasibility and cost of HCV elimination are not known.

Key Points
Question Is hepatitis C virus elimination
feasible in Pakistan, and what is
the cost?
Findings This decision analytical model

OBJECTIVES To investigate whether and under what conditions HCV elimination is feasible in

study found that an estimated 25 million

Pakistan and to estimate the cost of such elimination.

people would need to be screened every
year to diagnose 900 000 hepatitis C

DESIGN, SETTING, AND PARTICIPANTS This decision analytical model study used a

virus infections and 700 000 patients

microsimulation model of the HCV epidemic in Pakistan from 2015 to 2030. Using Pakistan-specific

would need treatment per year to

variables, the model simulated the landscape of HCV in Pakistan and evaluated the minimum

eliminate hepatitis C virus infection in

required screening and treatment rates needed to eliminate HCV in Pakistan. The study used

Pakistan. This strategy was estimated to

simulated individuals chronically infected with HCV from 2015 to 2030. The analysis was performed

be associated with 323 000 liver-

in 2018.

related deaths averted and cost savings
of $2.6 billion from 2015 to 2030.

INTERVENTIONS The status quo and 7 scenarios that can lead to HCV elimination in Pakistan by
2030, which were defined by different combinations of tests for screening, detection of viremia
before treatment, and confirmation of treatment response.

Meaning Substantial scale-up of
hepatitis C virus testing and treatment
may be essential to eliminate hepatitis C
virus infection in Pakistan, and such a

MAIN OUTCOMES AND MEASURES Temporal trends in HCV infection prevalence, mortality, and
disability-adjusted life-years and total cost of HCV infection care under the status quo and scenarios

strategy may be associated with cost
savings in the near future.

that can eliminate HCV by 2030.
RESULTS Under the status quo, from 2015 to 2030, 1.44 million people are projected to die of HCV
infection; 48% of deaths would be among people younger than 50 years. To achieve HCV elimination
in Pakistan, HCV testing would need to be scaled up to at least 25 million people to diagnose
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Author affiliations and article information are
listed at the end of this article.

900 000 persons and treatment to 700 000 people per year. Compared with the status quo, the
elimination scenario would avert 323 000 liver-related deaths and 13.0 million HCV-associated
disability-adjusted life-years from 2015 to 2030. The elimination scenario was associated with cost
savings of $2.6 billion from 2018 to 2030 with use of a point-of-care test for population-wide
antibody screening and detection of viremia and treatment response.
CONCLUSIONS AND RELEVANCE Substantial scale-up of HCV testing and treatment may be
essential to eliminate HCV infection in Pakistan, and such a strategy may be associated with cost
savings in the near future. Although HCV elimination in Pakistan may be ambitious, strategic planning
and strong support from the government may aid in its elimination.
JAMA Network Open. 2019;2(5):e193613. doi:10.1001/jamanetworkopen.2019.3613

Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(5):e193613. doi:10.1001/jamanetworkopen.2019.3613 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a University Of New Mexico User on 05/06/2022

May 10, 2019

1/12

JAMA Network Open | Global Health

Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan

Introduction
Chronic hepatitis C virus (HCV) infection is a global health problem that affects 70 million people
worldwide.1 It is associated with a substantial morbidity and mortality burden, and in 2015,
approximately 400 000 people died of HCV infection. Pakistan has a generalized epidemic of HCV
infection and one of the highest prevalence rates (4.9%) in the world, with 8 million to 11 million
individuals with active HCV viremia.1,2 Furthermore, most HCV-infected individuals in Pakistan
remain undiagnosed.2 Most HCV infections in Pakistan are transmitted through unsafe medical
practices, especially reuse of injection equipment in the health care setting.3 In addition, people who
inject drugs, although a small proportion of the population, have a high prevalence of infection,
ranging from 40% to 90%.4,5
The recent availability of new direct-acting antivirals (DAAs) offers an opportunity to eliminate
HCV. The World Health Assembly pledged to eliminate HCV as a public health threat (90% reduction
in HCV infection incidence and 65% reduction in HCV infection mortality) by 2030. To achieve this
elimination goal, 90% of HCV-infected people need to be diagnosed and 80% of eligible people
need to be treated by 2030.6
Despite the availability of DAAs, their high price in most high- and middle-income countries has
kept the treatment uptake low.7 However, in Pakistan, generic DAAs are available at a price as low as
$60 per treatment course, which represents one of the lowest prices worldwide. However, lack of a
systematic screening program could hinder elimination efforts. The Pakistan government recently
launched its first National Hepatitis Strategic Framework, which closely follows the World Health
Organization (WHO) global health sector strategy on viral hepatitis while accommodating for
Pakistan’s limited resources.2,8 However, critical gaps remain in identifying and testing HCV-infected
persons and linking them to treatment. Currently, no formal recommendations on populationbased screening for HCV in Pakistan have been made. In the absence of any screening program, the
goal to eliminate HCV by 2030 may remain unrealized.9
Furthermore, although the cost of treatment is low, the cost of diagnostic testing remains
substantial and is higher than the treatment cost in Pakistan. A large initial investment is likely
needed to scale up HCV testing and treatment to millions of HCV-infected individuals in Pakistan. The
amount of budget allocation and potential cost savings from these investments and the association
with different HCV testing algorithms for eliminating HCV are not known.1,10,11 Our objective was to
investigate whether and under what conditions HCV elimination is feasible in Pakistan, a country with
one of the highest burdens of HCV infection, and to estimate the cost of HCV elimination.

Methods
Overview
We adapted a previously developed mathematical model, Hepatitis C Disease Burden Simulation
(HEP-SIM), to simulate the landscape of HCV in Pakistan. The HEP-SIM model is an individual-level
state transition model that simulates the clinical management of HCV by incorporating HCV natural
history, different treatment waves, diagnosis rate, multiple testing algorithms, and access to antiviral
therapies (eFigure 1 in the Supplement) from 2015 to 2030.12-14 We adapted the HEP-SIM model
using Pakistan-specific data and used the model to project the disease and cost burden under the
status quo and HCV elimination scenario using different HCV testing algorithms. The analysis was
performed in 2018. All data used in this study were publicly available and therefore did not require
approval from an institutional review board. We followed the Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) reporting guideline.15 We describe the major model
components of the HEP-SIM model; further model details can be found elsewhere.12-14
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Patient Demographics
The base-case population in the HEP-SIM model represented HCV-infected patients in Pakistan. In
2008, the prevalence of chronic HCV infection was 4.9% (ie, 8.3 million people).16 The HCV
genotype, age and sex distributions, chronic stages of HCV infection, and antiviral treatment history
are detailed in eTable 1 and eTable 2 in the Supplement.

Natural History of HCV Infection
The natural history of HCV infection in the HEP-SIM model was defined using acute and chronic
phases of HCV infection, with chronic HCV infection defined using METAVIR fibrosis scores (F0, no
fibrosis; F1, portal fibrosis without septa; F3, numerous septa without fibrosis; and F4, cirrhosis),
decompensated cirrhosis, hepatocellular carcinoma, liver transplant, and liver-related death
(eFigure 2 in the Supplement). We used a published meta-analysis17 to estimate fibrosis progression
from F0 to F4 (eTable 3 in the Supplement). We estimated disease progression in HCV sequelae from
published observational studies.18-20 Because few liver transplants occur in Pakistan, we assumed
that liver transplant was not a viable option for patients with HCV infection.
We calibrated the annual incidence of HCV infection in Pakistan to 280 000 cases in 2014 and
assumed it changes proportional to the change in the prevalence of HCV infection over time. We
further conducted a sensitivity analysis considering that the incidence of HCV infection remains
constant at 280 000 cases per year1,21 and increases at an annual rate of 2%.10

Awareness and Screening for HCV Infection
We assumed that 95% of HCV-infected patients in Pakistan were not aware of their infection status
in 2001.22,23 Undiagnosed patients could become aware of their HCV status by sporadic testing or
through a screening program. We implemented sporadic HCV testing until 2017, reflecting the
current practice in Pakistan. We assumed that among those who were offered testing, 91% would
accept it and 90% of those who tested positive would receive those results.13,24 From 2018 onward,
we simulated 2 scenarios for HCV screening: (1) status quo and (2) HCV elimination screening
program, which was defined as 1-time HCV testing of all adults in Pakistan. Using our model, we
identified the minimum annual diagnosis rate and the treatment rate needed to achieve HCV
elimination by 2030, as defined by the WHO.

HCV Testing Algorithms
Under the status quo, we simulated screening based on tests currently used in Pakistan: antibody
test for screening, nucleic acid test (NAT) for detection of viremia, and assessment of treatment
response. For the HCV elimination scenario, we simulated 7 testing algorithms for diagnosis of HCV
infection.25,26 These included different combinations of tests for screening, detection of viremia
before treatment, and confirmation of sustained virologic response (SVR) status after treatment
(Table). The choice of these testing algorithms was based on the WHO testing guidance for middle-

Table. Different Hepatitis C Virus Testing Algorithms Evaluated to Scale Up Interventions in Pakistana
Testing
Algorithm

Screening Test

Detection of Viremia

Assessment of Hepatitis C Treatment
Response

T1 (base case)

Laboratory
based

Nucleic acid test

Nucleic acid test

T2

Laboratory
based

HCVcAg test

Nucleic acid test

T3

Point of care

Nucleic acid test

Nucleic acid test

T4

Point of care

GeneXpert

GeneXpert

T5

Point of care

HCVcAg test and nucleic acid test if
HCVcAg test result is negative

HCVcAg test

T6

Point of care

HCVcAg test and nucleic acid test if
HCVcAg test result is negative

Nucleic acid test

T7

Laboratory
based

GeneXpert

GeneXpert

Abbreviation: HCVcAg, hepatitis C virus core antigen.

JAMA Network Open. 2019;2(5):e193613. doi:10.1001/jamanetworkopen.2019.3613 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a University Of New Mexico User on 05/06/2022

a

Performance characteristics of each test are as
follows: point-of-care screening, 99.5% sensitivity
and 99.8% specificity; nucleic acid test, 99.8%
sensitivity and 99.7% specificity; GeneXpert, 99.8%
sensitivity and 99.7% specificity; HCVcAg test,
93.2% sensitivity and 98% specificity; and HCVcAg
test and nucleic acid test if HCVcAg test result is
negative, 99.8% sensitivity and 99.8% specificity.
May 10, 2019

3/12

JAMA Network Open | Global Health

Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan

and low-income countries as well as the strategies currently considered in Pakistan.

HCV Treatment Waves
We modeled antiviral treatment in different waves that reflected clinical practice in Pakistan:
pegylated interferon and ribavirin until 2015, followed by the availability of oral DAA combinations
from 2016 onward. We differentiated treatment regimens by treatment naive and experienced,
interferon tolerance status, and presence of cirrhosis, as described in a previous study.12 The SVR
rates of each type of treatment were estimated from real-world data and were based on HCV
genotype, fibrosis stage, and treatment history (eTable 4 in the Supplement). We further assumed
that patients who did not achieve SVR could receive treatment again 2 more times at most.

Treatment Uptake Rate
Because all patients with a diagnosis cannot be treated in a single year, we implemented an annual
treatment uptake rate defined by the number of patients who can receive HCV treatment each year.
We assigned priority to patients with F3 and F4 scores for HCV treatment, followed by patients with
F0 to F2 scores. We used historic data on the number of patients receiving antiviral treatment in
Pakistan (eTable 5 in the Supplement). Under the status quo, we assumed that the annual treatment
uptake rate would have stayed at the current rate of 160 650 per year from 2018 onward. In the HCV
elimination scenario, we determined the number needed to treat from 2018 onward to achieve HCV
elimination.

Costs
To evaluate the cost of HCV elimination, we incorporated the following 3 cost components from a
payer’s perspective: cost of HCV testing, cost of antiviral treatment,27 and cost of management of
HCV-associated health states (eAppendix and eTable 6 in the Supplement) To estimate the cost of
HCV testing, we calculated the number of people needed to screen to diagnose 1 HCV infection and
multiplied that number by the cost of testing antibody and viremia. We considered 7 different testing
algorithms using different tests and accounted for differences in their performance characteristics
and costs (Table and eTable 6 in the Supplement).25,26 We also accounted for the programmatic cost
of delivering the test. For DAA treatment, we used the price of $60 per treatment course27 and
added the cost of testing for assessing treatment response.27 We estimated HCV-associated health
state costs (scores of F0-F4, cirrhosis, and hepatocellular carcinoma) using the WHO Choosing
Interventions That Are Cost-effective (CHOICE) project (eTable 6 in the Supplement).

Model Outcomes
We projected temporal trends in HCV-associated disease burden in Pakistan under the status quo
and HCV elimination scenario, which was defined as the minimum required annual HCV screening
and treatment rate that would result in HCV elimination in Pakistan by 2030. To determine WHO’s
target of achieving a 90% diagnosis rate, we defined the diagnosis rate as the percentage of
diagnosed viremic cases and cured cases among the total population with HCV infection (ie, all
uncured and cured cases) and defined treatment coverage (80% target) as the percentage of cured
cases among the total population with HCV infection. We also estimated disability-adjusted lifeyears (DALYs) averted from scaling up HCV testing and treatment. To calculate DALYs, we used
disability weights defined by the Global Burden of Disease study28 (0 for scores of F0–F4, 0.194 for
decompensated cirrhosis, and 0.508 for hepatocellular carcinoma). We also conducted probabilistic
sensitivity analysis by accounting for uncertainty in all model variables and presented results using
95% credible intervals. We estimated the cost of HCV management under the status quo and HCV
elimination scenario for each of the 7 testing algorithms.
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Results
Feasibility of HCV Elimination in Pakistan
To achieve the WHO’s 2030 targets of HCV elimination in Pakistan, our model estimated that HCV
testing would need to be scaled up to at least 25 million people to diagnose at least 900 000 cases
per year from 2018 onward (Figure 1). Assuming the seroprevalence of 4.9%, these estimates
translate into screening 24.9 million individuals per year in the general population. In addition, the
treatment rate would need to be scaled up to at least 700 000 persons per year.

HCV Disease Burden: Status Quo vs Elimination Scenario
In 2015, the number of patients with viremia living in Pakistan was estimated at 8.27 million (95%
uncertainty interval [UI], 7.33 million to 9.12 million). Under the status quo, the number of patients
would decrease modestly to 7.25 million (95% UI, 6.07 million to 8.59 million) by 2030 (12%
reduction compared with 2015) (Figure 2A). During the same period, the number of cured patients
is projected to increase from 0.41 million (95% UI, 0.39 million to 0.42 million) in 2015 to 1.37 million
(95% UI, 1.14 million to 1.66 million) in 2030 (234% increase). In contrast, under the HCV elimination
scenario, the number of patients with viremia would decrease to 89 200 (95% UI, 29 800-1 211 204)
by 2030 (99% reduction compared with 2015) (Figure 2B), and the number of cured patients would
increase to 7.76 million (95% UI, 6.53 million to 8.27 million) in 2030 (1790% increase compared
with 2015).
In 2015, a total of 1.04 million (95% UI, 0.87 million to 1.25 million) individuals were aware of
their HCV infection (ie, a diagnosis rate of 12.0%). Under the status quo, the diagnosis rate by 2030
would moderately increase to 16.8% (Figure 2C). In contrast, under the HCV elimination scenario, the
diagnosis rate would increase to 99.9% by 2030 (Figure 2D).
We also projected the estimated incidence of HCV infection over time (Figure 3A). Under the
status quo, the incidence of HCV infection would decrease modestly from 281 000 cases per year
(95% UI, 250 800-307 900) in 2015 to 248 000 cases per year (95% UI, 208 500-292 400) in
2030 (12% decrease). In contrast, scaling up HCV diagnosis and treatment (HCV elimination
scenario) would substantially reduce HCV incidence to 9200 (95% UI, 1600-63 100) by 2030 (97%
decrease compared with 2015).
We estimated that in 2015, a total of 93 300 (95% UI, 41 400-129 100) people died of HCV
infection in Pakistan. Under the status quo, the annual number of HCV-related deaths would remain
relatively unchanged (Figure 3B). From 2015 to 2030, an estimated 1.44 million people (1.15 million
from 2018 to 2030) are projected to die of HCV infection in Pakistan; 48% of HCV-related deaths
would occur in people younger than 50 years (eFigure 3 in the Supplement). In 2015, HCV infection
was associated with 4.38 million (95% UI, 1.95 million to 6.05 million) DALYs (Figure 3C). Under the

Figure 1. Number of Persons Who Need to Be Diagnosed and Treated in Pakistan Each Year to Meet
the World Health Organization Target of Hepatitis C Virus Elimination
1 000 000

800 000

Diagnosed

No. of Persons

Treated
600 000

400 000

200 000

0
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
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status quo, cumulatively, 60.74 million DALYs were associated with HCV infection between 2015 and
2030. The HCV elimination scenario would decrease HCV-associated deaths to 32 600 (95% UI,
14 800-62 800) by 2030 (65% reduction compared with the 2015 value). This strategy would avert
323 000 liver-related deaths and 13.0 million HCV-associated DALYs from 2015 to 2030.
We also projected that the cumulative incidence of decompensated cirrhosis from 2015 to 2030
would decrease from 1.10 million under the status quo to 0.62 million (44% reduction) under the
HCV elimination scenario. Similarly, the cumulative incidence of hepatocellular carcinoma from 2015
to 2030 would decrease from 774 000 under the status quo to 547 000 new hepatocellular
carcinoma cases (29% reduction) under the HCV elimination scenario.

Cost of HCV Elimination
We estimated that the total cost of HCV management in 2018 was $684 million. Under the status
quo, the annual cost of HCV management would decrease modestly to $597 million by 2030
(Figure 4A); this projected decrease in costs was associated with deaths from HCV infection. Under
the HCV elimination scenario using currently recommended diagnostics (antibody for HCV screening
followed by nucleic acid testing for viremia diagnosis and assessment of treatment response [T1
algorithm]), the cost of HCV management would initially increase to $1.26 billion in 2018 but would
decrease substantially to $89 million by 2030. Testing algorithm T4 (point-of-care test for HCV

Figure 2. Number of Viremic (Aware and Unaware) and Cured Individuals in Pakistan From 2015 to 2030 Under Status Quo vs World Health Organization (WHO)
Hepatitis C Virus (HCV) Elimination Scenario
A Viremic and nonviremic persons under status quo

B
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the elimination scenario, the number of cured patients would exceed the number of
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viremic patients in year 2023. Bands show 95% uncertainty intervals generated by
probabilistic sensitivity analysis.
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screening, GeneXpert for detection of viremia, and GeneXpert for the assessment of treatment
response) yielded the lowest annual cost of $791 million in 2018, which is projected to decrease to
$64 million in 2030. The annual cost under this scenario would decrease below the annual cost under
the status quo in 2021 (ie, 3 years after scaling up screening and treatment).
Figure 4B shows the total costs of HCV management under the status quo and HCV elimination
scenario using 7 HCV testing algorithms. Under the status quo, the total cost of HCV management
from 2018 to 2030 would be $8.2 billion: $0.22 billion (2.7%) would be spent on HCV testing, $0.06

Figure 3. Annual Incidence of Hepatitis C Virus (HCV) Infection, Number of HCV-Associated Deaths,
and Disability-Adjusted Life-Years (DALYs) in Pakistan Under Status Quo and World Health Organization (WHO)
HCV Elimination Scenario From 2015 to 2030
A HCV incidence

HCV Annual Incidence, No. of Cases
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billion (0.7%) on antiviral treatment, and $7.93 billion (96.6%) on the management of HCV sequelae.
With use of the currently recommended diagnostic tests (T1), the total cost of HCV management
would be $10.0 billion: $5.54 billion (55.3%) would be spent on HCV testing, $0.51 billion (5.1%) on
antiviral treatment, and $3.96 billion (39.6%) on management of sequelae. Compared with the
status quo, the HCV elimination strategy would cost an additional $1.8 billion from 2018 to 2030. In
contrast, testing algorithms T3 to T7 would result in cost savings compared with the cost incurred
under the status quo. The T4 testing algorithm yielded the lowest total cost of HCV management of
$5.6 billion from 2018 to 2030, which would result in cost savings of $2.6 billion compared with the
status quo.

Scenario Analysis
We evaluated model outcomes under 3 scenarios: (1) incidence of HCV infection increased by 2% per
year, (2) HCV infection prevalence in 2018 was 20% higher (ie, 9.6 million instead of 8.0 million [base
case]), and (3) the HCV infection awareness rate in 2018 was 7% instead of 12.7% (base case). We
found that the annual diagnosis and treatment rates needed to eliminate HCV remained within 5% to
30% of the values reported in the base case (eTable 7 in the Supplement). In addition, the number
of deaths averted, DALYs averted, total cost of HCV elimination, and cost savings associated with
HCV elimination remained within 20% of the values estimated in the base case. Our results were
sensitive to the HCV incidence scenario: HCV elimination would not be feasible if the incidence does
not decrease over time.

Discussion
Our study projected the trajectory of HCV infection in Pakistan. On the basis of current HCV
management practices, the HCV burden ould continue to remain substantial in Pakistan. We
projected that from 2015 to 2030, a total of 1.44 million people could die of HCV infection and that
most patients with HCV infection would die young. Scaling up HCV testing and treatment could avert
323 000 liver-related deaths and as many as 13.0 million HCV-associated DALYs from 2015 to 2030,
ultimately resulting in HCV elimination by 2030. Furthermore, scaling up HCV testing using
innovative diagnostics could save $2.6 billion during the same period.

Figure 4. Cost of Hepatitis C Virus (HCV) Management From 2018 to 2030 Under Status Quo vs World Health Organization (WHO) HCV Elimination Scenario
A Annual cost

B

Total cost
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of annual cost of HCV management under status quo vs WHO elimination scenario using
different testing algorithms (as defined in the Table). B, Total cost of HCV management
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elimination by 2030. Testing algorithms T3 through T7 were associated with cost savings
compared with the cost under status quo. The T4 algorithm provided the lowest cost of
HCV management ($5.6 billion) and was associated with $2.6 billion in cost savings
compared with the cost of status quo ($8.2 billion) (triangles).
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We found that HCV elimination is feasible in Pakistan; however, substantial efforts are
needed—at least 25 million people would need to be screened every year to diagnose 900 000 HCV
infections, and at least 700 000 patients would need treatment per year. This capacity target,
representing a 4-fold increase in treatment and 24-fold increase in diagnosis compared with the
current rates, may serve as important guideposts to determine progress toward achieving the overall
goal of HCV elimination by 2030. Our results emphasize that HCV elimination in Pakistan may not be
feasible without meeting these intermediate capacity targets.
Our results underscore the urgency to accelerate the diagnosis of HCV infection and identify the
millions of individuals with undiagnosed HCV infection. Although HCV testing and treatment scale-up
are happening in Pakistan, treatment uptake is happening at a faster rate than testing. Several HCV
microelimination projects are under way, and these projects play an important role in identifying
infected individuals and linking them to treatment. Elimination of HCV in Pakistan will require
screening of the general population because of the diffuse nature of the country’s epidemic of HCV
infection; this is challenging but could be optimized through first targeting subpopulations with
higher prevalence and improving their linkage to treatment after diagnosis. The lessons learned from
these initial efforts can then be extended to other subgroups with intermediate prevalence.
Increasing the diagnosis and treatment capacity would also require an initial investment, but
our results show that such a strategy could be cost saving in the long term, especially if innovative
approaches are used for confirming the diagnosis. In particular, we found that using a point-of-care
test for antibody screening and HCV core antigen/GeneXpert for confirmation of SVR may reduce the
overall cost of HCV elimination by 21% compared with a strategy that relies on current diagnostics.
If the cost of new diagnostics could be further reduced, the amount of cost savings could be greater
than $2.6 billion.
Although HCV elimination in Pakistan may be ambitious, we believe that strong support from
the government and strategic planning can make elimination a reality. The foundation of scaling up
testing and treatment has already been set up through Pakistan’s Hepatitis Prevention and
Treatment Program.29 Efforts could focus on establishing a national policy for screening the general
population for HCV infection, setting screening and testing targets for local health facilities, skill
building of health care workers to expand access to screening and treatment, increasing availability
of low-cost diagnostics and treatment, simplifying of diagnosis and treatment algorithms, and
expanding the infrastructure for a telehealth (such as the Extension for Community Healthcare
Outcomes project) surveillance system to monitor progress across care cascade and outcomes. In
addition, innovative financing mechanisms could be explored to raise money needed to scale up HCV
screening and treatment in Pakistan.
The benefit of HCV treatment would also extend beyond those related to slowing progression
of liver disease in individuals with HCV infection; successful testing and treatment would be key in
the primary prevention of HCV infection by stemming the ongoing risk of primary infections and
additional infections. Reducing the incidence of HCV infection may be key to achieving HCV
elimination in Pakistan.
We chose Pakistan for this analysis because it has a high prevalence of HCV infection and a large
number of infected individuals.30 Our results have direct implications for other countries with a high
burden of HCV infection. We believe that the WHO targets will not be met unless there is a strong
political will and focused effort at both the public and the private levels. Other countries have
successfully implemented large-scale initiatives to screen and identify infected individuals. For
instance, the Ministry of Health and Population of Egypt set the target to screen 15 million people in
2018.31 Elimination of HCV in Pakistan would also need to take precedent among the many
competing social issues facing low-income or middle-income nations to prevent millions of deaths
due to an otherwise curable disease.
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Limitations
Our study has some limitations. We do not explicitly differentiate between subsequent infection and
new infection. Reliable estimates of the incidence of HCV infection in Pakistan are lacking; therefore,
we assumed the new incidence to be proportional to the prevalence. We did not include the role of
infection prevention interventions in reducing the incidence of HCV infection. Implementing such
programs, along with education of practitioners and payers, may be associated with faster reduction
in the incidence of HCV infection; thus, our study could have overestimated the incidence of HCV
infection. We did not account for the competing risk of mortality from cardiovascular diseases and
other infections in patients with HCV infection, which could have resulted in overestimation of the
benefits of HCV treatment. However, we also did not account for extrahepatic benefits of HCV
treatment, which could have resulted in underestimation of the benefits of HCV treatment. We did
not account for the cost associated with strengthening the infrastructure to provide mass screening
in Pakistan; therefore, our study could have overestimated cost savings associated with HCV
elimination. We accounted for only health care–associated costs and excluded societal costs;
inclusion of those costs would have increased the magnitude of cost savings.

Conclusions
Our study provides insights on the feasibility and cost of HCV elimination in Pakistan. The findings
suggest that by substantially scaling up diagnosis and treatment, HCV infection can be eliminated in
Pakistan, which may be associated with 323 000 deaths and 13 million HCV-associated DALYs
averted from 2018 to 2030. Programs on HCV elimination will require initial investment, but such
upfront investment may lead to cost savings in the near future.
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